Metacrine, Inc.
3985 Sorrento Valley Blvd
Suite C
San Diego
CA
92121
United States
Website: http://www.metacrine.com/
About Metacrine, Inc.
We are a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal, or GI, diseases. Our most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. We have leveraged our chemistry and biology platform to internally discover a proprietary portfolio of non-bile acid FXR agonists. We purposefully designed MET409, our lead product candidate, to be an optimized, next-generation FXR agonist that we are initially developing as a potentially differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, we plan to evaluate MET409 as a potential first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease. Beyond our FXR program, we are building a pipeline of novel drug candidates against other drug targets by taking advantage of our drug discovery and development capabilities.
58 articles about Metacrine, Inc.
-
Metacrine to Participate in Upcoming Investor Conferences
11/23/2020
Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the following December investor conferences
-
Metacrine Reports Business Updates and Third Quarter 2020 Financial Results
11/12/2020
Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH
-
Metacrine to Present New Data from MET409 Program in NASH at AASLD’s The Liver Meeting Digital Experience™
10/1/2020
Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that two posters highlighting new data on the company’s lead clinical candidate, MET409,
-
Metacrine Announces Pricing of Initial Public Offering - Sep 16, 2020
9/16/2020
Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, announced the pricing of its initial public offering of 6,540,000 shares of its common stock at a public offering price of $13.00 per share.
-
It was a busy week for biopharma, biotech and medical device initial public offerings (IPOs). Here’s a look.
-
BioSpace Movers & Shakers, Sept. 4
9/4/2020
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Metacrine Strengthens Leadership Team with Key Appointments
9/2/2020
Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced the appointments of Catherine Lee as senior vice president, general counsel and Theresa Lowry as vice president, human resources. “We are pleased to welcome Cathy and Theresa to the Metacrine team at this exciting time in the company’s evolution,” sai
-
Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress™ 2020
8/27/2020
MET409 demonstrated notable improvements in decreased liver fat content and differentiated impacts on pruritus and LDL cholesterol after 12 weeks of treatment in NASH patients
-
Metacrine Announces MET409 Receives FDA Fast Track Designation for the Treatment of NASH
8/25/2020
Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH). “We are very pleased that MET409 has rece
-
Metacrine Appoints Pharmaceutical Business and R&D Executive, Preston Klassen, M.D., MHS, as President and Chief Executive Officer
6/9/2020
John McHutchison, AO, M.D., Appointed to Board of Directors Adding Significant Industry Experience and Drug Development Expertise
-
Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients
1/22/2020
Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, announced topline results from a 12-week, randomized, placebo-controlled study of MET409 in patients with non-alcoholic steatohepatitis (NASH).
-
Metacrine to Present at Jefferies 2019 London Healthcare Conference
11/18/2019
Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 7:40 a.m. ET (12:40pm GMT).
-
Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist
7/9/2019
Placebo-controlled, multi-center trial will evaluate safety, tolerability and efficacy biomarkers to assess potential best-in-class FXR agonist
-
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
-
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
-
Movers and Shakers for Sept. 10
9/10/2018
Let's take a look at who made a splash in the pharma and biotech world the past week. -
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
-
Metacrine Completes $22M Series B to Advance Best-in-Class FXR Program Into Clinical Development
12/7/2017
Metacrine today announced it has closed a $22M Series B financing led by new investor NEA, along with participation from existing investors ARCH, Polaris, venBio, and Alexandria Venture Investments.